2 COVID-19 Antibody Stocks to Buy Right Now
Luckily, there are over 300 coronavirus treatment candidates currently in various stages of preclinical and clinical studies. If successful antibody therapeutics could be developed to treat and prevent SARS-CoV-2 infections, they could be game-changers in the fight against the disease that's caused worldwide economic shutdowns and killed almost 200,000 people in the U.S. alone. GlaxoSmithKline (NYSE: GSK) and Regeneron (NASDAQ: REGN) are two companies leading the way in developing prospective antibody treatments for COVID-19.